Search company, investor...
Novus Therapeutics company logo

Novus Therapeutics

novustherapeutics.com

Stage

IPO | IPO

Total Raised

$83.44M

Date of IPO

9/17/2014

Market Cap

0.03B

Stock Price

2.51

About Novus Therapeutics

Novus Therapeutics is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each with the potential to be developed for multiple indications. The company's lead program (OP0201) is a surfactant-based nasal aerosol drug-device combination product candidate being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media, which is middle ear inflammation and effusion with or without infection.

Headquarters Location

19900 MacArthur Blvd. Suite 550

Irvine, California, 92612,

United States

949-238-8090

Missing: Novus Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Novus Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Novus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Novus Therapeutics is included in 4 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

M

Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health IT

7,901 items

Novus Therapeutics Patents

Novus Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Antiandrogens
  • Estrogens
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/21/2017

9/18/2018

Graphical projections, Technical drawing, Balloons (aircraft), Roadsters, Aircraft configurations

Grant

Application Date

8/21/2017

Grant Date

9/18/2018

Title

Related Topics

Graphical projections, Technical drawing, Balloons (aircraft), Roadsters, Aircraft configurations

Status

Grant

Latest Novus Therapeutics News

Atlas Venture Welcomes Jodie Morrison as Venture Partner

Jul 12, 2021

See original article here -> post Before that, she served as president and chief executive officer of Tokai Pharmaceuticals, Inc. where she led the 2014 IPO and 2016 merger, and held …… Related

Novus Therapeutics Frequently Asked Questions (FAQ)

  • Where is Novus Therapeutics's headquarters?

    Novus Therapeutics's headquarters is located at 19900 MacArthur Blvd., Irvine.

  • What is Novus Therapeutics's latest funding round?

    Novus Therapeutics's latest funding round is IPO.

  • How much did Novus Therapeutics raise?

    Novus Therapeutics raised a total of $83.44M.

  • Who are the investors of Novus Therapeutics?

    Investors of Novus Therapeutics include Apple Tree Partners, Novartis Venture Funds, Qualifying Therapeutic Discovery Project and Queensland BioCapital Funds.

  • Who are Novus Therapeutics's competitors?

    Competitors of Novus Therapeutics include Aquinox Pharmaceuticals, Bexion Pharmaceuticals, Rigel Pharmaceuticals, CoLucid Pharmaceuticals, VentiRx Pharmaceuticals and 13 more.

Compare Novus Therapeutics to Competitors

P
Prolexys Pharmaceuticals

Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.

F
Favrille

Favrille is a developer of cancer and autoimmune disease immuno-therapeutics.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

K
KeyNeurotek Pharmaceuticals

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

N
NexGenix Pharmaceuticals Holdings

NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.